The Latest
Investigational PrEP Injection, Dosed Every Other Month, Beats Daily PrEP in Phase 3 Study
New data presented at AIDS 2020 show the long-acting injectable drug cabotegravir proved superior to daily oral TDF/FTC for MSM and transgender women.
Body Mass Index Among People With HIV Is Rising Much Faster Than the General Population
People living with HIV in the U.S. are experiencing increases in body mass index at a rate three times greater than that of the general U.S. population, according to new research presented at AIDS 2020.
HIV Care and Coronavirus (COVID-19): The Latest Info and Guidance
Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.
This Week in HIV Research: So Many Relative Risks
July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.
Does Taking HIV Meds Reduce the Odds of COVID-19? Experts Say, ‘Not So Fast’
A newly published study linking HIV medication to reduction in COVID-19 risk has many problems, experts warn.
This Week in HIV Research: Closing Our Care Chasms
June 25, 2020: 25 years of HOPS; successes of San Francisco’s test-and-treat program; missed opportunities to test people who inject drugs; how patient-provider trust can curb prescribing cascades.
This Week in HIV Research: Existing Solutions Won't Close the Race Gap
June 18, 2020: Existing evidence-based interventions aren't enough to close HIV's racial gap; transgender patient outcomes in the HIV care continuum; meeting long-term needs of formerly incarcerated people; acute respiratory illness severity and HIV status.
New Study Shows Effectiveness of On-Demand PrEP
Kaiser Permanente’s 2-1-1 pre-exposure prophylaxis (PrEP) program shows event-driven dosing works.
This Week in HIV Research: Setting a New Bar
June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.
When People Stop Newer HIV Meds, Time to Viral Rebound Not Better Than With Older Antiretroviral Therapy, NIH Study Finds
Researchers are trying to understand treatment interruptions as part of work to develop a future HIV cure and therapies that will not involve medications.